Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.
| Revenue (Most Recent Fiscal Year) | $74.21M |
| Net Income (Most Recent Fiscal Year) | $-521.96M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 34.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.69 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2775.77% |
| Net Margin (Trailing 12 Months) | -2769.04% |
| Return on Equity (Trailing 12 Months) | -47.46% |
| Return on Assets (Trailing 12 Months) | -39.33% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.79 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.79 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.35 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.88 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.83 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.22 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 138.24M |
| Free Float | 116.12M |
| Market Capitalization | $721.60M |
| Average Volume (Last 20 Days) | 1.29M |
| Beta (Past 60 Months) | 1.24 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 65.32% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |